The earnings call reflected strong commercial and financial performance, driven by the success of the Tryngolza launch and a robust pipeline. Despite some uncertainties in clinical study outcomes and competitive landscapes, the overall sentiment is positive due to significant revenue growth and strategic execution.

Company Guidance

During Ionis's second quarter 2025 financial results conference call, the company highlighted significant momentum, resulting in an upward revision of their 2025 financial guidance. The standout performance of Tryngolza, the first FDA-approved treatment for familial chylomicronemia syndrome (FCS), exceeded expectations with $19 million in net product sales for the quarter, marking a threefold increase from the previous quarter. The company now anticipates total 2025 Tryngolza revenues between $75 million and $80 million. The call also covered the anticipated FDA approval of Donidalorsen for hereditary angioedema, expected next month, which, alongside the strong Tryngolza performance, supports Ionis's elevated financial outlook. The company reported a twofold year-over-year revenue increase to $452 million for the quarter, contributing to a $154 million non-GAAP net income. This robust performance enabled Ionis to improve its operating loss projection to between $300 million and $325 million and forecast a year-end cash balance of approximately $2 billion.

Successful Launch of Tryngolza

Tryngolza, the first FDA-approved treatment for familial chyloymicronemia syndrome, exceeded revenue expectations with $19 million in net product sales for the second quarter, reflecting a threefold increase quarter-over-quarter.

Record Revenue and Increased Financial Guidance

Ionis reported $452 million in revenue for Q2, a twofold increase year-over-year, and raised the 2025 revenue guidance by $100 million to $850 million.

Strong Pipeline Progress

Anticipated FDA approval for Donidalorsen for HAE next month, with potential launches for Olezarsen and Zilganersen in the pipeline, representing significant revenue potential.

Early Commercial Success and Strategic Execution

The commercial team reached over 3,000 physicians, with favorable payer dynamics leading to over 90% of patients paying $0 out-of-pocket for Tryngolza.

Ionis Pharmaceuticals (IONS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IONS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-1.23 / -	-0.95	―	―	―
Jul 30, 2025	2025 (Q2)	-0.09 / 0.70	-0.45	255.56% (+1.15)
Apr 30, 2025	2025 (Q1)	-1.10 / -0.93	-0.98	5.10% (+0.05)
Feb 19, 2025	2024 (Q4)	-1.12 / -0.66	-0.06	-1000.00% (-0.60)
Nov 06, 2024	2024 (Q3)	-1.14 / -0.95	-1.03	7.77% (+0.08)
Aug 01, 2024	2024 (Q2)	-0.94 / -0.45	-0.6	25.00% (+0.15)
May 07, 2024	2024 (Q1)	-1.05 / -0.98	-0.87	-12.64% (-0.11)
Feb 21, 2024	2023 (Q4)	-0.80 / -0.06	-0.37	83.78% (+0.31)
Nov 02, 2023	2023 (Q3)	-1.01 / -1.03	-0.33	-212.12% (-0.70)
Aug 09, 2023	2023 (Q2)	-0.88 / -0.60	-0.74	18.92% (+0.14)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IONS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$41.48	$43.37	+4.56%
Apr 30, 2025	$29.81	$30.71	+3.02%
Feb 19, 2025	$31.95	$31.81	-0.44%
Nov 06, 2024	$38.80	$39.04	+0.62%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Ionis Pharmaceuticals (IONS) report earnings?

Ionis Pharmaceuticals (IONS) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).

What is Ionis Pharmaceuticals (IONS) earnings time?

Ionis Pharmaceuticals (IONS) earnings time is at Oct 30, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IONS EPS forecast?

IONS EPS forecast for the fiscal quarter 2025 (Q3) is -1.23.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing